Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: A comprehensive review

International Journal of Neuroscience

Volumn 122, Issue 11, 2012, Pages 619-629

  Yanuck, Danielle ^a   Mihos, Christos G ^b   Santana, Orlando ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Brain; CNS; Neurology; Non lipid lowering; Statins

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN C; APOLIPOPROTEIN E; ATORVASTATIN; BETA1A INTERFERON; CAROTENOID; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN; UBIDECARENONE;

ADD ON THERAPY; ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; BEHAVIOR CHANGE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL (TOPIC); DELIRIUM; DEMENTIA; DEMYELINATION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENCEPHALITIS; GENE EXPRESSION; GLASGOW COMA SCALE; GLIA CELL; HIPPOCAMPUS; HUMAN; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; MUSCLE CRAMP; NEUROFIBRILLARY TANGLE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW (TOPIC); TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY; VASOSPASM;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867563393     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.704455     Document Type: Review

References (106)

1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM,Mosca L, Pasternak RC, Pearson T, PfefferMA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363-72.
2. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388-91.
3. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: A comprehensive review. Rheumatol Int. 2012;32(2):287-94.
4. Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med. 2011;4:261-71.
5. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: A comprehensive review. Cardiol Rev. 2010;18(6):298-304.
6. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Indian J Pharmacol. 2005;37(2):77-85.
7. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
8. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143-50.
9. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M,Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack.NEngl JMed. 2006;355(6):549-59.
10. Ni Chró in'in D, Callaly EL, Duggan J, Merwick Á, Hannon N, Sheehan Ó, Marnane M, Horgan G, Williams EB, Harris D, Kyne L, McCormack PM, Moroney J, Grant T, Williams D, Daly L, Kelly PJ. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: The North Dublin Population Stroke Study. Stroke. 2011;42(4):1021-29.
11. Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Statins after ischemic stroke of undetermined etiology in young adults. Neurology. 2011;77(5):426-30.
12. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-63.
13. Sugawara T, Ayer R, Zhang JH. Role of statins in cerebral vasospasm. Acta Neurochir Suppl. 2008;104:287-90.
14. Lapchak PA, HanMK. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolyticinduced intracerebral hemorrhage in embolized rabbits. Brain Res. 2009;1303:144-50.
15. Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke. 2001;32(12):2817-20.
16. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743-51.
17. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95(15):8880-85.
18. Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M, Balduini W, Paoletti R, Tremoli E. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23(2):322-27.
19. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-67.
20. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M,Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack.NEngl J Med. 2006;355(6):549-56.
21. Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database Syst Rev. 2011;(8):CD007551.
22. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, Klingman JG, Sidney S, Hills NK, Sorel M, Cullen SP, Johnston SC. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43(1):147-54.
23. Blanco M, Nombela F, Castellanos M, Rodriguez-Y'anez M, Garc'ia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, D'avalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology. 2007;69(9):904-10.
24. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39(2):497-502.
25. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, SillesenH, Zivin JA,Welch KM. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24 Pt 2):2364-70.
26. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y,Mrkobrada M. Statins and intracerebral hemorrhage: Collaborative systematic review andmeta-analysis. Circulation. 2011;124(20):2233-42.
27. Biffi A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, Viswanathan A, Rost NS, Smith EE, Goldstein JN, Greenberg SM, Rosand J. Statin use and outcome after intracerebral hemorrhage: Case-control study and metaanalysis. Neurology. 2011;76(18):1581-88.
28. Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage: Preliminary results of a populationbased study. Stroke. 2002;33(5):1190-95.
29. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology. 2000;55(7):947-51.
30. Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: A decision analysis. Arch Neurol. 2011;68(5):573-79.
31. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: A meta-analysis. Stroke. 2008;39(9):2622-26.
32. Kramer AH, Fletcher JJ. Statins in the management of patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. Neurocrit Care. 2010;12(2): 285-96.
33. Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins inmultiple sclerosis: Immune modulation, neuroprotection and neurorepair. Future Neurol. 2008;3(2):153.
34. Weber MS, Zamvil SS. Statins and demyelination. Curr Top Microbiol Immunol. 2008;318:313-24.
35. Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia. 2009;57(2):182-93.
36. Ifergan I, Wosik K, Cayrol R, K'ebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis. Ann Neurol. 2006;60(1):45-55.
37. Correale J, Villa A. The blood-brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting. Autoimmunity. 2007;40(2):148-60.
38. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007;55(2):130-43.
39. Miron VE, Zehntner SP, Kuhlmann T, Ludwin SK, Owens T, Kennedy TE, Bedell BJ, Antel JP. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880-90.
40. Togha M, Karvigh SA, NabaviM,Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: A double-blind randomized controlled trial. Mult Scler. 2010;16(7):848-54.
41. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450-54.
42. Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, Oturai A,Malmestrom C, Stenager E, Sellebjerg F, Sondergaard HB. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomized phase 4 trial. Lancet Neurol. 2011;10(8):691-701.
43. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical andmolecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989-93.
44. Birnbaum G, Cree B, Altafullah I, ZinserM, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390-95.
45. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-81.
46. Whitfield JF. Can statins put the breaks on Alzheimer's disease? Expert Opin Investig Drugs. 2006;15(12):1479-85.
47. Kurinami H, Sato N, Shinohara M, Takeuchi D, Takeda S, Shimamura M, Ogihara T, Morishita R. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int JMol Med. 2008;21(5):531-37.
48. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 2011;230(1):27-34.
49. Harris JR, Milton NG. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47-75.
50. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol. 2009;68(3):314-25.
51. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69(9):878-85.
52. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-17.
53. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008;13(2): 187-97.
54. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3-7.
55. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26.
56. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormickW, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58(7):1311-17.
57. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-17.
58. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31.
59. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, MurphyMB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85-90.
60. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-64.
61. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549-57.
62. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009;29(43):13543-56.
63. Bar-On P, Crews L, Koob AO,Mizuno H, Adame A, Spencer B, Masliah E. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem. 2008;105(5):1656-67.
64. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol. 2010;221(2):267-74.
65. Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W, Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: The association with antiinflammatory responses. PLoS one. 2011;6(6):e20945.
66. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother. 1999;53(3):141-45.
67. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist. 2011;17(3):244-55.
68. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
69. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. ArchNeurol. 2012;69(3):380-84.
70. Mutez E, Duhamel A, Defebvre L, Bordet R, Dest'ee A, Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol Res. 2009;60(1):41-45.
71. B'eziaud T, Ru Chen X, El Shafey N, Fr'echou M, Teng F, Palmier B, Beray-Berthat V, Soustrat M, Margaill I, Plotkine M, Marchand-Leroux C, Besson VC. Simvastatin in traumatic brain injury: Effect on brain edema mechanisms. Crit Care Med. 2011;39(10):2300-7.
72. Abrahamson EE, Ikonomovic MD, Dixon CE, DeKosky ST Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol. 2009;66(3):407-14.
73. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206(1):59-69.
74. Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: A translational approach. J Neurotrauma. 2012;29(7):1388-400.
75. Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008;25(8):1011-17.
76. Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma. 2011;71(4):815-19.
77. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: An analysis of individual case safety reports from vigibase. Drug Saf. 2007;30(6):515-25.
78. Sørensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413-17.
79. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223-28.
80. Golomb BA, Kwon EK, Koperski S, EvansMA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: An analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32(8):649-61.
81. Beltowski J. Statins and ALS: The possible role of impaired LXR signaling. Med Sci Monit. 2010;16(3):RA73-78.
82. Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc. 2009;57(2):237-42.
83. Cemeus C, Zhao TT, BarrettGM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol. 2008;90(1):9-17.
84. Bar EE, Stearns D. New developments in medulloblastoma treatment: The potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs. 2008;17(2):185-95.
85. Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, Zhu J, Duan RS. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol. 2011;271(2):455-61.
86. Sarkey JP, Richards MP, Stubbs EB Jr. Lovastatin attenuates nerve injury in an animal model of Guillain-Barr'e syndrome. J Neurochem. 2007;100(5):1265-77.
87. Tsakiri A, Tsiantoulas D, Frederiksen J, Svane IM. Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol. 2010;221(2):320-28.
88. Patassini S, Giampa C, Martorana A, Bernardi G, Fusco FR. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett. 2008;448(1):166-69.
89. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, MooreWS, Nixon JV, Pearson TA. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517-84.
90. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227-76.
91. Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain-Barr'e syndrome on initiation of statin therapy. Muscle Nerve. 2004;30(5):663-66.
92. Scola RH, Trentin AP, Germiniani FM, Piovesan EJ,Werneck LC. Simvastatin-induced mononeuropathy multiplex: Case report. Arq Neuropsiquiatr. 2004;62(2B):540-42.
93. Abell'an-Miralles I, S'anchez-P'erez RM, P'erez-Carmona N, D'iaz-Mar'in C, Mallada-Frech'in J. Multiple mononeuropathy associated to treatment with pravastatin. Rev Neurol. 2006;43(11):659-61.
94. Miesbach W, Chapman J, Scharrer I. Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome. J Neurol Sci. 2005;238(1-2):93-95.
95. Serbanescu I, Ryan MA, Shukla R, Cortez MA, Snead OC 3rd, Cunnane SC. Lovastatin exacerbates atypical absence seizures with only minimal effects on brain sterols. J Lipid Res. 2004;45(11):2038-43.
96. Frederiksen JL. Simvastatin as an add-on treatment to copaxone for the treatment of relapsing multiple sclerosis. Glostrup University Hospital. Clinicaltrial gov NCT00429442.
97. Frederiksen JL. Simvastatin treatment of patients with acute optic neuritis. Glostrup University Hospital. Clinicaltrial gov NCT00261326.
98. Valone F. Immunotherapy with BHT-3009 alone or combined with atorvastatin in patients with multiple sclerosis. Clinicaltrial gov NCT00103974.
99. Damier P. Safety and efficacy of pravastatin in relapsingremitting multiple sclerosis. Nantes University Hospital. Clinicaltrial gov NCT00200655.
100. Matsumoto M. Japan statin treatment against recurrent stroke (J-STARS). Hiroshima University. Clinicaltrial gov NCT00221104.
101. Heo JH. The effects of very early use of rosuvastatin in preventing recurrence of ischemic stroke. Severance Hospital. Clinicaltrial gov NCT01364220.
102. Migrino R. Carotid plaque regression with statin treatment assessed by high fieldmagnetic resonance imaging.Medical College of Wisconsin. Clinicaltrial gov NCT00388843.
103. Kazui H. The clinical study of pitavastatin treatment for group of mild to moderate Alzheimer's disease. Osaka University. Clinicaltrial gov NCT00548145.
104. Carlsson CM. To evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in AD patients. Pfizer. Clinicaltrial gov NCT00151502.
105. Figueiredo E. The role of statins in preventing cerebral vasospasm secondary to subarachnoid hemorrhage. University of Sao Paulo General Hospital. Clinicaltrial gov NCT01346748.
106. Diringer M. Statins and cerebral blood flow in subarachnoid hemorrhage.Washington University School of Medicine. Clinicaltrial gov NCT00795288.